etidronate and Cholera Infantum studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Research Excerpts

Excerpt	Relevance	Reference
"We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis."	9.15	Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011)
" We have evaluated etidronate disodium, a diphosphonate commonly prescribed in the United Kingdom for Paget's disease in patients with rheumatoid arthritis."	9.06	A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. ( Bird, HA; Dixon, JS; Hill, J; Sitton, NG; Wright, V, 1988)
"We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis."	5.15	Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011)
" We have evaluated etidronate disodium, a diphosphonate commonly prescribed in the United Kingdom for Paget's disease in patients with rheumatoid arthritis."	5.06	A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. ( Bird, HA; Dixon, JS; Hill, J; Sitton, NG; Wright, V, 1988)
"To evaluate the frequency of upper gastrointestinal (GI) tract adverse events associated with risedronate during two (2-year) randomized, double-blind, parallel-group, placebo-controlled studies."	2.71	Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. ( Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005)
"The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%."	2.52	Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. ( Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015)
"etidronate) have been associated with acute renal failure."	2.44	Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007)
"Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens."	2.43	Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. ( Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006)
" The risk of an adverse upper GI event increases when these drugs are used concurrently with nonsteroidal anti-inflammatory drug (NSAID) therapy, but this incidence is no more than that observed with concurrent placebo and NSAID therapy."	2.41	Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. ( Baker, DE, 2002)
" Some bisphosphonates have been associated with upper gastrointestinal (GI) tract adverse effects."	2.41	Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. ( Adami, S; Bolognese, MA; Ernst, TF; Ettinger, MP; Josse, RG; Lindsay, R; Mulder, H; Roberts, A; Stevens, KP; Taggart, H; Zippel, H, 2002)
" Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise."	1.35	Comparative gastrointestinal safety of weekly oral bisphosphonates. ( Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009)
" The most frequently reported adverse events are gastrointestinal complaints and oesophageal ulcers."	1.32	[Psychiatric side effects associated with diphosphonate treatment]. ( van der Klauw, MM; Wolffenbuttel, BH, 2003)
"The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice."	1.32	Tolerability and compliance with risedronate in clinical practice. ( Hamilton, B; McCoy, K; Taggart, H, 2003)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (15.38)	18.7374
1990's	3 (11.54)	18.2507
2000's	14 (53.85)	29.6817
2010's	5 (19.23)	24.3611
2020's	0 (0.00)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention[NCT05204836]			Phase 1	56 participants (Anticipated)	Interventional	2023-05-16	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. Journal of endocrinological investigation, 2015, Volume: 38, Issue:2 Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointesti	2015
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fem	2012
Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Reviews in gastroenterological disorders, 2002, Volume: 2, Issue:1 Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Digestive System; Dr	2002
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Maturitas, 2006, Apr-20, Volume: 54, Issue:1 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administra	2006
Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug safety, 2007, Volume: 30, Issue:9 Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho	2007
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top	2007
Adverse effects of bisphosphonates. A comparative review. Drug safety, 1996, Volume: 14, Issue:3 Topics: Acute Kidney Injury; Animals; Diphosphonates; Etidronic Acid; Gastrointestinal Diseases; Humans; Ost	1996
The use of risedronate in Paget's disease. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Fibrous Dysplasia,	1999
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clinic proceedings, 2002, Volume: 77, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clinical Trials, Phase III as	2002
Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP). Clinical orthopaedics and related research, 1977, Issue:127 Topics: Alkaline Phosphatase; Bone and Bones; Calcitonin; Calcium; Deafness; Etidronic Acid; Fractures, Bone	1977

Article	Year
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. Clinical endocrinology, 2011, Volume: 74, Issue:6 Topics: Aged; Alkaline Phosphatase; Asian People; Bone Density; Bone Density Conservation Agents; Cholecalci	2011
Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. Mayo Clinic proceedings, 2005, Volume: 80, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; D	2005
Treatment of Paget's disease of bone with alendronate. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Resorption; Etidronic Acid;	1999
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milan, Italy), 2001, Volume: 13, Issue:5 Topics: Alendronate; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Gastrointestinal	2001
Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Annals of internal medicine, 1977, Volume: 87, Issue:6 Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Matrix; Clinical Trials as Topic; Etidronic	1977
A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. Clinical rheumatology, 1988, Volume: 7, Issue:1 Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Bone and Bones; Clinical Trials as Topic; E	1988

Article	Year
Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos	2009
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:4 Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fem	2009
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate. Calcified tissue international, 2010, Volume: 87, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, F	2010
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA). Calcified tissue international, 2011, Volume: 89, Issue:3 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Rela	2011
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain? Mayo Clinic proceedings, 2002, Volume: 77, Issue:10 Topics: Alendronate; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Osteoporosis, Postmenopausal	2002
[Psychiatric side effects associated with diphosphonate treatment]. Nederlands tijdschrift voor geneeskunde, 2003, Jan-04, Volume: 147, Issue:1 Topics: Adult; Attention; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Male; M	2003
Tolerability and compliance with risedronate in clinical practice. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2003, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Gastrointe	2003
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents;	2005
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clinical therapeutics, 2006, Volume: 28, Issue:2 Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Databases, Factual; Drug Administr	2006
[Diphosphonate for the prevention of an increased ossification process]. Klinische Wochenschrift, 1986, Jun-16, Volume: 64, Issue:12 Topics: Diphosphonates; Etidronic Acid; Gastrointestinal Diseases; Humans; Ossification, Heterotopic; Osteit	1986

etidronate and Cholera Infantum

Research Excerpts

Research

Studies (26)

Authors

Clinical Trials (1)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Fadda, V	1
Maratea, D	1
Trippoli, S	1
Messori, A	1
Cadarette, SM	1
Katz, JN	1
Brookhart, MA	1
Stürmer, T	1
Stedman, MR	1
Levin, R	1
Solomon, DH	1
Blumentals, WA	1
Harris, ST	1
Cole, RE	1
Huang, L	1
Silverman, SL	2
Ralston, SH	1
Kou, TD	1
Wick-Urban, B	1
Steinbuch, M	1
Masud, T	1
Roux, C	1
Goldstein, JL	1
Zhou, X	1
Klemes, A	1
Lindsay, R	2
Chung, HY	1
Chin, SO	1
Kang, MI	1
Koh, JM	1
Moon, SH	1
Yoon, BK	1
Yoon, HK	1
Chung, YS	1
Park, HM	1
Landfeldt, E	1
Lang, A	1
Robbins, S	1
Ström, O	1
Baker, DE	1
Tremaine, WJ	1
Khosla, S	1
Wolffenbuttel, BH	1
van der Klauw, MM	1
Hamilton, B	1
McCoy, K	1
Taggart, H	2
Barrera, BA	1
Wilton, L	1
Harris, S	1
Shakir, SA	1
Adami, S	4
Pavelka, K	1
Cline, GA	1
Hosterman, MA	1
Barton, IP	1
Cohen, SB	1
Bensen, WG	1
Epstein, S	1
Delmas, PD	1
Emkey, R	2
Wilson, KM	1
Hiltbrunner, V	1
Schimmer, RC	1
Penning-van Beest, FJ	1
Goettsch, WG	1
Erkens, JA	1
Herings, RM	1
Strampel, W	1
Civitelli, R	1
Kishimoto, H	1
Zamberlan, N	1
Lombardi, A	1
Miller, PD	2
Adachi, JD	1
Olszynski, WP	1
Kendler, DL	1
Licata, AA	1
Li, Z	1
Gomez-Panzani, E	1
Bolognese, MA	1
Ettinger, MP	1
Mulder, H	1
Josse, RG	1
Roberts, A	1
Zippel, H	1
Ernst, TF	1
Stevens, KP	1
Rashid, M	1
Khairi, A	1
Johnston, C	1
Khairi, MR	1
Altman, RD	1
DeRosa, GP	1
Zimmermann, J	1
Schenk, RK	1
Johnston, CC	1
Forth, W	1
Bird, HA	1
Hill, J	1
Sitton, NG	1
Dixon, JS	1
Wright, V	1